#China #Shanghai #Parkinson's Disease #iPSC therapy #UniXell

UniXell Biotechnology: Pioneering Dual Approvals in Parkinson's Treatment

In a remarkable achievement, UniXell Biotechnology Co., Ltd has announced that it has received the Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for its innovative therapy, UX-DA003. This allogeneic induced pluripotent stem cell (iPSC) therapy is specifically designed for treating Parkinson's disease. The recent FDA approval closely follows a similar endorsement from China's National Medical Products Administration (NMPA) on June 3, 2026, establishing a historic dual clearance for this ground-breaking therapy.

This dual approval not only underscores the significance of UX-DA003 in the realm of neurodegenerative disease treatments but also positions UniXell's clinical strategies as forward-thinking in the biotechnology sector. The company is set to carry out concurrent clinical development in both China and the United States, a move that exemplifies its ambitious drive for innovation and patient accessibility.

UX-DA003 represents a sophisticated therapy approach, primarily focusing on midbrain dopaminergic progenitor cells derived from allogeneic iPSCs. The foundation of this therapy lies in UniXell's proprietary technologies, including the SISBAR lineage tracing platform and a high-precision directed differentiation system. With a focus on clinical-grade, GMP-compliant iPSC seed cell banks, this candidate demonstrates remarkable genetic stability and consistency in achieving differentiation, satisfying rigorous regulatory standards in both territories.

Advantages of UX-DA003

Comprehensive preclinical studies have showcased UX-DA003’s industry-leading safety and therapeutic efficacy, revealing several notable benefits:

1. Ultra-High Purity: The therapy achieves a functional dopaminergic neuron representation of 50-60% in grafts, significantly surpassing the existing industry average of 2-15%.
2. Optimized Dosage: The therapy's formulation allows for a reduction in clinical dosage requirements by 50-80%, thereby enhancing its cost-effectiveness compared to traditional cell therapies.
3. Long-Term Safety: Tracking of cell proliferation revealed only a 0.23% increase at six months post-transplantation, which is safer compared to a reported range of 0.5-11% in existing therapies.

These features position UX-DA003 as a frontrunner in the field of standardized clinical applications for allogeneic iPSC therapy in Parkinson's disease treatment.

A Vision for the Future

The accomplishment of FDA clearance represents four major regulatory milestones reached by UniXell in a swift three-month period, which encompasses key pipeline projects targeting Parkinson's disease and drug-resistant epilepsy. The company's Parkinson's therapy portfolio embodies two distinctive yet complementary technical pathways:

• - UX-DA001: This autologous iPSC therapy, currently in Phase I clinical trials at Ruijin Hospital in Shanghai, serves as a personalized approach based on the patient’s own cells, thus minimizing immune rejection risks. Preliminary insights suggest a favorable safety profile following a year of follow-up with the first enrolled patient.
• - UX-DA003: The allogeneic iPSC therapy is designed for wider availability, scalability, and cost-efficiency, making it suitable for large-scale clinical deployments.

As Lanlin Wu, the CEO of UniXell Biotechnology, commented on this milestone, the dual pathways for autologous and allogeneic iPSC therapies not only accommodate different patient needs but also catalyze the rapid industrialization of regenerative medicine utilizing iPSCs.

The dual regulatory filings submitted by UniXell streamline the compliance process, supported by a unified iPSC cell platform and standardized manufacturing operations. This endeavor strengthens the groundwork for the international launch of the company’s allogeneic therapy pipeline.

Conclusion

UniXell Biotechnology stands on the brink of a new era in Parkinson’s disease therapies, as their innovative approach not only tackles the disease on multiple fronts but also reflects a commitment to provide accessible and effective treatment solutions for patients worldwide. The road ahead promises exciting developments, with the ongoing parallel clinical development in both the U.S. and China paving the way for the global commercialization of their pioneering therapies in neurodegenerative diseases.